镁信健康发布数据+AI解决方案 构建创新药多元支付智能生态

Core Insights - The eighth China International Import Expo (CIIE) is currently being held in Shanghai, where Shanghai Meixin Health Technology Group Co., Ltd. launched its AI + data intelligence central platform, mind42.ai, including the mind42.med multi-payment intelligent decision-making platform for the pharmaceutical industry [1] - Major international and local companies such as AstraZeneca, Bristol-Myers Squibb, Pfizer China, Roche, and Zai Lab are the first partners of the mind42.med platform [1] - In July, the National Healthcare Security Administration and the National Health Commission issued a document establishing the "Commercial Insurance Innovative Drug Catalog," marking a significant step in promoting commercial insurance support for innovative drugs and medical devices [1] Company and Industry Summary - The mind42.ai series products are based on a full-chain data approach of "insurance-pharmaceutical-channel," aimed at providing intelligent decision support for pharmaceutical companies in a multi-payment environment, facilitating the commercialization of innovative drugs in China [2] - The platform has accumulated approximately 400 million claims data details, focusing on the entry and claims data of commercial insurance and high-potential channel claims, while also incorporating essential drug information, prescription data, epidemiological data, and macroeconomic data [2] - The system can identify high-potential hospitals, track the treatment duration of commercial insurance patients, and quantify new potential based on patient profiles, thereby enhancing the efficiency of commercial resources [2] - Leveraging AI capabilities, the system can predict market potential and trends, generate diverse payment commercialization strategies, and support natural language interaction, presenting information lists and data dashboards [2] - The company believes that the era of multi-payment for innovative drugs has arrived, and the intelligent decision-making platform will empower the commercialization process of innovative drugs in China, facilitating a positive cycle of "investment-research-return" [2]